Ignite Creation Date:
2024-05-06 @ 12:44 AM
Last Modification Date:
2024-10-26 @ 10:53 AM
Study NCT ID:
NCT01640444
Status:
COMPLETED
Last Update Posted:
2019-04-11
First Post:
2012-06-13
Brief Title:
Influence of BRAF and PIK3K Status on the Efficacy of 5-FluorouracilLeucovorinOxaliplatin FOLFIRI Plus Bevacizumab or Cetuximab in Patients With RAS Wild-type Metastatic Colorectal Carcinoma and 3 Circulating Tumor Cells CTC
Sponsor:
Spanish Cooperative Group for the Treatment of Digestive Tumours TTD
Organization:
Spanish Cooperative Group for the Treatment of Digestive Tumours TTD
Organization Data
Organization:
Spanish Cooperative Group for the Treatment of Digestive Tumours TTD
Class:
OTHER
Study ID:
TTD-12-02
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Spanish Cooperative Group for the Treatment of Digestive Tumours TTD
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Roche Pharma AG | INDUSTRY |